1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

Interview: Galapagos Pipeline In Good Shape

 
• By Kevin Grogan

Following more promising rheumatoid arthritis data on filgotinib at EULAR, the Belgian biotech's chief medical officer Walid Abi-Saab tells Scrip about the JAK inhibitor's promise in a number of other indications.

Arrow
Many strings to Galapagos R&D bow • Source: Shutterstock

Galapagos NV is pushing ahead with one of the largest pipelines in the biotech sector and while there is much attention on the JAK1 inhibitor filgotinib, the Belgian firm believes it also has game-changing therapies in other areas, notably osteoarthritis.

Speaking to Scrip at the European League Against Rheumatism congress in Madrid, chief medical officer Walid Abi-Saab talked initially about...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

How To Score A Win With Real-World Evidence In India

 
• By Vibha Ravi

Bharat Serums showed it’s possible to score a regulatory win with real-world evidence (RWE) studies in India when it ran one leading to a label expansion for its mAb trinbelimab. As cell and gene therapies and rare disease drugs gain currency, sponsors could look at takeaways from the RhYTHM study.

Genentech Adds Lupus Nephritis To Cancer Indications On Gazyva’s Label

 
• By Joseph Haas

Seeking to compete with GSK’s Benlysta, the Roche unit obtains the first FDA approval of an anti-CD20 agent in lupus nephritis, a complication of lupus that can lead to end-stage kidney disease.

Hansoh/Roche ADC Deal Caps Chinese One-Day Licensing Spree

 
• By Dexter Jie Yan

Multiple Chinese biopharma firms reach new deals with major Western and other partners in a spree of licensing deals over a one-day period, with ADCs, in vivo CAR and bifunctional fusion protein therapies among the target assets.

J&J’s Duato Expects Eventual Alignment With White House Policy Priorities

 
• By Joseph Haas

Following Pfizer and AstraZeneca’s US drug-pricing deals with the Trump Administration, the CEO said J&J continually has sought common ground with the White House.

More from Therapy Areas

Summit Presses Ahead With Ivonescimab Filing Despite Approval Doubts

 
• By Andrew McConaghie

Frontrunner believes it can gain a first approval in EGFR+ lung cancer, even though the FDA recently raised the bar on overall survival.

Neuphoria To Look At Strategic Options After BNC210 Fails In Social Anxiety

 
• By Alaric DeArment

Neuphoria said that its Phase III trial of BNC210 in social anxiety disorder did not meet the primary or secondary endpoints, but its PTSD program will continue.

ESMO 25: Ovarian Cancer Data Validates Tubulis ADC Platform

 
• By Kevin Grogan

Positive first-in-human data for TUB-040 represent "a momentous milestone" for the German biotech, according to its CEO Dominik Schumacher.